215 related articles for article (PubMed ID: 38674150)
21. In Vivo Synaptic Density Imaging with
Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
[No Abstract] [Full Text] [Related]
22. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Arcaroli JJ; Touban BM; Tan AC; Varella-Garcia M; Powell RW; Eckhardt SG; Elvin P; Gao D; Messersmith WA
Clin Cancer Res; 2010 Aug; 16(16):4165-77. PubMed ID: 20682712
[TBL] [Abstract][Full Text] [Related]
23. Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Du G; Wang J; Zhang T; Ding Q; Jia X; Zhao X; Dong J; Yang X; Lu S; Zhang C; Liu Z; Zeng Z; Safadi R; Qi R; Zhao X; Hong Z; Lu Y
Cell Death Dis; 2020 Feb; 11(2):118. PubMed ID: 32051399
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
25. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Renouf DJ; Moore MJ; Hedley D; Gill S; Jonker D; Chen E; Walde D; Goel R; Southwood B; Gauthier I; Walsh W; McIntosh L; Seymour L
Invest New Drugs; 2012 Apr; 30(2):779-86. PubMed ID: 21170669
[TBL] [Abstract][Full Text] [Related]
26. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
[TBL] [Abstract][Full Text] [Related]
27. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
28. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
29. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Posadas EM; Ahmed RS; Karrison T; Szmulewitz RZ; O'Donnell PH; Wade JL; Shen J; Gururajan M; Sievert M; Stadler WM
Prostate; 2016 Feb; 76(3):286-93. PubMed ID: 26493492
[TBL] [Abstract][Full Text] [Related]
30. Anti-allergic effect of the Src family kinase inhibitor saracatinib.
Yamaki K; Terashi M; Ogura S; Inoue S; Naka N; Nakagaki T; Oka N; Koyama Y
Pharmazie; 2020 Jul; 75(7):339-343. PubMed ID: 32635977
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
32. Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Siemann DW; Dong M; Pampo C; Shi W
Cell Tissue Res; 2012 Aug; 349(2):541-50. PubMed ID: 22526632
[TBL] [Abstract][Full Text] [Related]
33. Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
Chiu LY; Hsin IL; Tsai JN; Chen CJ; Ou CC; Wu WJ; Sheu GT; Ko JL
J Cell Physiol; 2021 Feb; 236(2):1148-1157. PubMed ID: 32686156
[TBL] [Abstract][Full Text] [Related]
34. Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
Dalton RN; Chetty R; Stuart M; Iacona RB; Swaisland A
Anticancer Res; 2010 Jul; 30(7):2935-42. PubMed ID: 20683035
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
[TBL] [Abstract][Full Text] [Related]
36. Current status of SRC inhibitors in solid tumor malignancies.
Puls LN; Eadens M; Messersmith W
Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.
Hu M; Che P; Han X; Cai GQ; Liu G; Antony V; Luckhardt T; Siegal GP; Zhou Y; Liu RM; Desai LP; O'Reilly PJ; Thannickal VJ; Ding Q
J Pharmacol Exp Ther; 2014 Oct; 351(1):87-95. PubMed ID: 25047515
[TBL] [Abstract][Full Text] [Related]
38. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Nakachi I; Helfrich BA; Spillman MA; Mickler EA; Olson CJ; Rice JL; Coldren CD; Heasley LE; Geraci MW; Stearman RS
Clin Transl Sci; 2016 Dec; 9(6):293-301. PubMed ID: 27766744
[TBL] [Abstract][Full Text] [Related]
39. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.
Smith LM; Zhu R; Strittmatter SM
Neuropharmacology; 2018 Mar; 130():54-61. PubMed ID: 29191754
[TBL] [Abstract][Full Text] [Related]
40. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
